Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium.
Hum Vaccin Immunother. 2013 Jan;9(1):115-21. doi: 10.4161/hv.22342.
Seasonal influenza in healthy working-age adults accounts for a substantial part of the socioeconomic burden of this disease. Intanza® 9 µg (sanofi pasteur) is a microneedle-delivered intradermal trivalent inactivated influenza vaccine approved in 2009 for the prevention of seasonal influenza in adults 18 to 59 years of age. The microneedle system reliably and reproducibly delivers the vaccine to the dermis. Clinical studies show that Intanza 9 µg is as immunogenic and as well tolerated in working-age adults as a reference intramuscular trivalent inactivated vaccine. Local reactions to Intanza 9 µg, mainly erythema, are transient, mostly mild or moderate, and do not affect acceptability. Intanza 9 µg is considered satisfactory by at least 95% of both vaccinees and prescribers, especially because of the short needle and rapid administration. Because Intanza® 9 µg offers an alternative to intramuscular vaccines, it might help increase influenza vaccine coverage rates.
在健康的成年劳动者中，季节性流感占这种疾病造成的相当一部分社会经济负担。Intanza® 9 µg（赛诺菲巴斯德）是一种微针给药的皮内三价灭活流感疫苗，于 2009 年获得批准，用于预防 18 至 59 岁成年人的季节性流感。微针系统可靠且可重复地将疫苗递送至真皮。临床研究表明，Intanza 9 µg 在成年劳动者中的免疫原性和耐受性与参考肌肉内三价灭活疫苗相当。Intanza 9 µg 的局部反应主要为红斑，是短暂的，大多数为轻度或中度，并不影响可接受性。Intanza 9 µg 被至少 95%的疫苗接种者和处方者认为是满意的，尤其是因为它的短针和快速给药。由于 Intanza® 9 µg 提供了一种肌肉内疫苗的替代方案，它可能有助于提高流感疫苗接种率。
